16 results on '"Wang, Zhe-Hai"'
Search Results
2. Clinical outcomes of patients with or without common AEs in anlotinib cohort: Subgroup analysis of the ALTER0303 trial
- Author
-
Ying Cheng, Xiuwen Wang, Wang Zhe-Hai, Haiyong Wang, Qiming Wang, Jie Liu, Yi Luo, Jun Guo, Liyan Liu, Jianhua Shi, Jianxing He, Baohui Han, Kejun Nan, Xiao Han, Kai Li, Yuankai Shi, Lin Wu, Chao Xie, Weiqiang Chen, and Li Zhang
- Subjects
Cancer Research ,medicine.medical_specialty ,integumentary system ,Oncology ,business.industry ,Internal medicine ,Cohort ,medicine ,Subgroup analysis ,cardiovascular diseases ,Adverse effect ,business ,Hand-Foot Syndrome - Abstract
e20507 Background: In ALTER 0303, the common adverse reaction (AE) included hypertension (HTN) and hand foot syndrome (HFS). In this subgroup analysis, we aim to assess the relationship between common AEs and clinical benefit in anlotinib cohort. Methods: Eligible patients showed disease progression after second-line or further treatment were randomly assigned in a 2:1 ratio to receive 12 mg/day of anlotinib or placebo. The primary endpoint was overall survival (OS). This subgroup analysis was based on anlotinib cohort. Results: Patients with HTN had significantly improved median OS, median progress-free survival (PFS), objective response (ORR) and disease control rate (DCR) compared with patients without HFS in anlotinib cohort. Similarly, patients with HFS had better clinical outcomes in anlotinib cohort. Not surprisingly, patients occurred both HFS and HTN had more superior medium OS compared with only HFS, only HTN and neither HFS nor HTN. Conclusions: HTN or HFS is associated with better clinical outcomes in advanced NSCLC patients received anlotinib. Clinical trial information: NCT02388919. [Table: see text]
- Published
- 2019
3. The efficacy of anlotinib in squamous cell carcinoma (SCC) patients with or without hypertension in ALTER0303: Anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer (NSCLC)
- Author
-
Weiqiang Chen, Xiuwen Wang, Jian Dong, Baohui Han, Ying Cheng, Jianhua Shi, Lin Wu, Li Zhang, Yuankai Shi, Yi Luo, Wang Zhe-Hai, Kai Li, Baolan Li, Kejun Nan, Faguang Jin, Jianxing He, and Qiming Wang
- Subjects
Cancer Research ,medicine.drug_class ,business.industry ,Third-line therapy ,non-small cell lung cancer (NSCLC) ,medicine.disease ,Tyrosine-kinase inhibitor ,Oncology ,medicine ,Overall survival ,Cancer research ,Basal cell ,In patient ,Anlotinib Hydrochloride ,business ,neoplasms - Abstract
e20503 Background: As a promising multi-target tyrosine kinase inhibitor (TKI), anlotinib hydrochloride significantly improved overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients in the phase 3 trial (ALTER0303). Here, we demonstrated the efficacy of anlotinib in SCC patients with or without hypertension. Methods: Patients (n = 439) were randomized in a 2:1 ratio to receive anlotinib (12mg daily for 14 days in a 21 day cycle) or placebo. The primary endpoint was OS and second endpoints were PFS, ORR, DCR and QoL. The correlation between hypertension and efficacy (PFS and OS) was analyzed in SCC patients treated with anlotinib. Results: For different ECOG score (0 and 1) SCC patients (n = 46) in the anlotinib arm, the PFS was significantly improved in patients with hypertension in ECOG 1 group (7.00 vs 4.83 months, p = 0.043). There is no statistical difference in other subgroups. Moreover, for the SCC patients in anlotinib arm, PFS was significantly prolonged in patients with hypertension compared to the patients without hypertension (7.23 vs 3.23 months; HR = 0.36; 95% CI, 0.16–0.84; P = 0.001). However, the median OS of the patients with hypertension was numerically but not statistically longer than the patients without hypertension (13.93 vs 6.30 months; HR = 0.56; 95%CI, 0.26-1.22; P = 0.100). Conclusions: In the ALTER0303 trial, anlotinib significantly improved PFS with a potential benefit of OS for SCC patients with hypertension. And ECOG score does not affect the efficacy of anlotinib in SCC patients with or without hypertension. Clinical trial information: NCT02388919. [Table: see text]
- Published
- 2019
4. Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib
- Author
-
Xinyang Liu, Leizhen Zheng, Pagona Lagiou, Yuxian Bai, Weijian Guo, Jin Li, Ying Cheng, Jianping Xiong, Hao Yu, Shukui Qin, Jianming Xu, Nong Xu, Yan Yang, Guoping Sun, Zhichao Wang, T. Liu, Wang Zhe-Hai, and Liwei Wang
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,medicine.disease ,Metastatic gastric cancer ,chemistry.chemical_compound ,chemistry ,Potential biomarkers ,Internal medicine ,medicine ,Apatinib ,In patient ,Adverse effect ,business - Abstract
4052 Background: Reliable biomarkers of apatinib response in gastric cancer (GC) are lacking. We investigated the association between early presence of common adverse events (AEs) and clinical outcomes in metastatic GC patients. Methods: We conducted a retrospective cohort study using data on 269 apatinib-treated GC patients in two clinical trials. AEs were assessed at baseline until 28 days after the last dose of apatinib. Clinical outcomes were compared between patients with and without hypertension (HTN), proteinuria or hand and foot syndrome (HFS) in the first 4 weeks using Kaplan–Meier methods, Cox proportional hazard regression and logistic regression models. Landmark analyses were performed as sensitivity analyses. Predictive model and risk scores were analyzed to predict overall survival (OS). Results: Presence of AEs in the first 4 weeks was associated with prolonged median OS (169 vs. 103 days, log-rank p=0.0039; adjusted hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.64-0.84, p=0.001), prolonged median progression-free survival (PFS, 87 vs. 62 days, log-rank p=0.0309; adjusted HR 0.69, 95%CI 0.53-0.91, p=0.007), and increased disease control rate (54.67% vs. 32.77%; adjusted odds ratio 2.67, p
- Published
- 2017
5. Tumour Necrosis Factor-α Gene Polymorphism Is Associated with Metastasis in Patients with Triple Negative Breast Cancer
- Author
-
Li, Hui-Hui, primary, Zhu, Hui, additional, Liu, Li-Sheng, additional, Huang, Yong, additional, Guo, Jun, additional, Li, Jie, additional, Sun, Xin-Ping, additional, Chang, Chun-Xiao, additional, Wang, Zhe-Hai, additional, and Zhai, Kan, additional
- Published
- 2015
- Full Text
- View/download PDF
6. Association of Chemotherapy-induced Leucopenia with Treatment Outcomes in Advanced Non-small-cell lung Cancer Cases Receiving the NP Regimen
- Author
-
Huang, Cheng-Suo, primary, Liu, Lin, additional, Liu, Jie, additional, Chen, Zhen, additional, Guo, Jun, additional, Li, Chang-Zheng, additional, Zhou, Deng-Guang, additional, and Wang, Zhe-Hai, additional
- Published
- 2012
- Full Text
- View/download PDF
7. A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma
- Author
-
S. Qin, L. Wang, M. Tao, Y. Yang, Y. Bai, N. Xu, Wang Zhe-Hai, W. j. Guo, L. Zheng, J. p. Xiong, J. Xu, J. Li, G. Sun, and Y. Cheng
- Subjects
Oncology ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,ECOG Performance Status ,Placebo ,Surgery ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Toxicity ,medicine ,Clinical endpoint ,Apatinib ,In patient ,Adverse effect ,business - Abstract
4019 Background: Apatinib at a daily dose of 850mg was tolerable from our phase I study. The objective of this study was to evaluate the efficacy and safety of apatinib in patients with advanced or metastatic gastric cancer after failure of two lines of chemotherapy. Methods: Inclusion criteria were ECOG performance status ≤ 1, measurable disease and adequate organ functions. Patients were randomized to the placebo (A), 850mg qd (B), and 425mg bid (C) arm. Study treatment was continued as a 28-day cycle until progression or intolerable toxicity. Tumor assessments were performed after cycle 2, 3, and then every 2 cycle thereafter. The primary endpoint was progression-free survival (PFS). The secondary endpoints were disease-free control rate (DCR), objective response rate (ORR), and overall survival (OS). All adverse events were reported using CTCAE v3.0). COX analysis method was used. Results: 141 patients were enrolled. Results were presented in the table. Treatment-related toxicities of each arm was 8 (...
- Published
- 2011
8. Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
- Author
-
Yang JJ, Zhang Y, Wu L, Hu J, Wang ZH, Chen JH, Fan Y, Lin G, Wang QM, Yao Y, Zhao J, Chen Y, Fang J, Song Y, Zhang W, Cheng Y, Guo RH, Li XY, Shi HP, Xue WZ, Han D, Zhang PL, and Wu YL
- Abstract
Purpose: The KUNPENG study aimed to evaluate the efficacy and safety of vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition ( MET ), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring c-Met alterations., Methods: This multicenter, multicohort, open-label, single-arm, phase II trial enrolled patients with c-Met dysregulated, locally advanced or metastatic NSCLC from January 2020 to August 2022 across 17 centers. Cohort 1 included patients with MET exon 14 skipping ( MET ex14)-mutant NSCLC who had not previously received MET inhibitors. Participants were administered vebreltinib at a dosage of 200 mg twice a day in 28-day cycles. The primary end point was the objective response rate (ORR), and the key secondary end point was the duration of response (DoR), both evaluated by a blinded independent review committee according to the RECIST version 1.1., Results: As of August 9, 2022, 52 patients had been enrolled in cohort 1, of whom 35 (67.3%) were treatment-naïve. The ORR reached 75% (95% CI, 61.1 to 86). Among treatment-naïve patients, the ORR was 77.1% (95% CI, 59.9 to 89.6), and in previously treated patients, it was 70.6% (95% CI, 44.0 to 89.7). The disease control rate was 96.2%, with a median DoR of 15.9 months, a median progression-free survival of 14.1 months, and a median overall survival of 20.7 months. The most common treatment-related adverse events were peripheral edema (82.7%), QT prolongation (30.8%), and elevated serum creatinine (28.8%)., Conclusion: Vebreltinib has shown promising efficacy and a favorable safety profile in patients with MET ex14-mutant NSCLC.
- Published
- 2024
- Full Text
- View/download PDF
9. The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.
- Author
-
Wang Y, Hu GF, and Wang ZH
- Abstract
Background: Indoleamine 2,3-dioxygenase (IDO) catalyzes the rate-limiting step of tryptophan (Trp) degradation via the kynurenine (Kyn) pathway, which inhibits the proliferation of T cells and induces the apoptosis of T cells, leading to immune tolerance. Therefore, IDO has been considered as the most important mechanism for tumor cells to escape from immune response. Previous studies suggested that IDO might be involved in the progression of tumor and resistance to chemotherapy. Several preclinical and clinical studies have proven that IDO inhibitors can regulate IDO-mediated tumor immune escape and potentiate the effect of chemotherapy. Thus, the present study investigated the correlation between the clinical parameters, responses to chemotherapy, and IDO activity to provide a theoretical basis for the clinical application of IDO inhibitors to improve the suppression status and poor prognosis in cancer patients., Methods: The serum concentrations of Trp and Kyn were measured by high-performance liquid chromatography in 252 patients with stage IIIB or IV non-small-cell lung cancer, and 55 healthy controls. The IDO activity was determined by calculating the serum Kyn-to-Trp (Kyn/Trp) ratio., Results: The IDO activity was significantly higher in the lung cancer patients than in the controls (median 0.0389 interquartile range [0.0178-0.0741] vs 0.0111 [0.0091-0.0133], respectively; P <0.0001). In addition, patients with adenocarcinoma had higher IDO activity than patients with nonadenocarcinoma (0.0449 [0.0189-0.0779] vs 0.0245 [0.0155-0.0563], respectively; P =0.006). Furthermore, patients with stage IIIB disease had higher IDO activity than patients with stage IV disease (0.0225 [0.0158-0.0595] vs 0.0445 [0.0190-0.0757], respectively; P =0.012). The most meaningful discovery was that there was a significant difference between the partial response (PR) patients and the stable disease (SD) and progressive disease (PD) patients (0.0240 [0.0155-0.0381] vs 0.0652 [0.0390-0.0831] vs 0.0868 [0.0209-0.0993], respectively, P <0.0001)., Conclusion: IDO activity was increased in lung cancer patients. Higher IDO activity correlated with histological types and disease stages of lung cancer patients, induced the cancer cells' resistance to chemotherapy, and decreased the efficacy of chemotherapy., Competing Interests: Disclosure The authors report no conflicts of interest in this work.
- Published
- 2017
- Full Text
- View/download PDF
10. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
- Author
-
Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, and Wang ZH
- Subjects
- Antineoplastic Combined Chemotherapy Protocols administration & dosage, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine therapeutic use, Disease-Free Survival, Erlotinib Hydrochloride adverse effects, Humans, Neoplasm Recurrence, Local drug therapy, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Deoxycytidine analogs & derivatives, Drug-Related Side Effects and Adverse Reactions diagnosis, Erlotinib Hydrochloride administration & dosage, Erlotinib Hydrochloride therapeutic use, Pancreatic Neoplasms drug therapy
- Abstract
Background: Pancreatic cancer is considered as a chemoresistant neoplasm with extremely dismal prognosis. Gemcitabine is recommended as the standard agent for locally advanced or metastatic pancreatic cancer. A series of trials have been conducted to improve the outcome of advanced pancreatic cancer with other anticancer drugs in combination with gemcitabine. Unfortunately, the designers of the clinical trials failed to improve the poor prognosis of patients with advanced pancreatic cancer. Erlotinib was the first additional drug that improved the overall survival of patients with advanced pancreatic cancer with gemcitabine. We performed this systematic review and meta-analysis to explore the efficacy and safety of the combination of gemcitabine with erlotinib (GemErlo) for patients with advanced pancreatic cancer using the currently available evidence., Methods: PubMed/MEDLINE, EMBASE, the Cochrane Library, and relevant abstracts of major conferences were comprehensively searched. Data results on objective response rate, disease control rate, and 1-year survival were pooled by using MetaAnalyst with a random-effects model. Results on progression-free survival and overall survival were only summarized descriptively., Results: A total of 24 studies with 1,742 patients with locally advanced or metastatic pancreatic cancer treated with GemErlo were included. Combined objective response rate was 14.4% (95% CI: 11.6%-17.7%), disease control rate was 55.0% (95% CI: 51.5%-58.5%), and 1-year survival rate was 28.5% (95% CI: 24.0%-33.4%). Progression-free survival ranged from 2.63 to 9.6 months, and overall survival varied from 6 to 10 months. As for the toxicity profile, the most common adverse events (AEs) were hematologic reactions, skin rash, and gastrointestinal reactions. Other severe AEs, which had low incidence, included treatment-induced death and interstitial lung disease., Conclusion: Our study showed that GemErlo is associated with reasonable activity in treating patients with locally advanced or metastatic pancreatic cancer. Most of the AEs were tolerable, while some severe AEs needed careful detection.
- Published
- 2016
- Full Text
- View/download PDF
11. Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer.
- Author
-
Liu J, Song B, Wang JL, Li ZJ, Li WH, and Wang ZH
- Subjects
- Adult, Aged, Alleles, Female, Haplotypes, Humans, Male, Middle Aged, Multivariate Analysis, Prognosis, Regression Analysis, Risk Factors, Treatment Outcome, Interleukin-10 genetics, Polymorphism, Genetic, Promoter Regions, Genetic, Stomach Neoplasms genetics
- Abstract
Aim: To evaluate the association between of the interleukin-10 (IL-10) promoter polymorphisms and survival of advanced gastric cancer (GC) patients., Methods: The IL-10 (-1082, rs1800896; -819, rs1800871; and-592, rs1800896) genotypes in 234 patients with advanced gastric cancer and in 243 healthy controls were determined by polymerase chain reaction-restriction fragment length polymorphism assay. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by unconditional logistic regression for the associations between IL-10 genotypes and the risk of GC. The Kaplan-Meier method with log-rank testing was used to evaluate the association between genotype and survival of the patients., Results: The IL-10 -1082 G allele and GCC (-1082, -819 and -592) haplotype were associated with increased gastric cancer risks (OR 1.2, 95% CI 0.6-3.2, P = 0.007, for -1082 G allele, OR = 2.3, 95% CI, 1.2-4.1, P = 0.005, for GCC haplotype, respectively). However, none of the three IL-10 gene polymorphisms (-1082, -819 and -592) was correlated with gastric cancer survival (P > 0.05), and none of the genotypes of the three IL-10 sites was found as independent prognostic risk factors in the multivariate test., Conclusion: IL-10 gene promoter polymorphisms may not be associated with the prognosis of advanced gastric cancer.
- Published
- 2011
- Full Text
- View/download PDF
12. [Clinical analysis of 23 lung cancer patients accompanied by pulmonary embolism].
- Author
-
Shao L, Wang ZH, and Zuo JY
- Subjects
- Adenocarcinoma complications, Adenocarcinoma drug therapy, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Blood Gas Analysis, Echocardiography, Electrocardiography, Female, Humans, Lung Neoplasms drug therapy, Magnetic Resonance Imaging, Male, Middle Aged, Pulmonary Embolism blood, Pulmonary Embolism diagnosis, Retrospective Studies, Survival Rate, Tomography, Spiral Computed, Urokinase-Type Plasminogen Activator therapeutic use, Anticoagulants therapeutic use, Lung Neoplasms complications, Pulmonary Embolism drug therapy, Pulmonary Embolism etiology, Warfarin therapeutic use
- Abstract
Background and Objective: Pulmonary embolism (PE) is a common complication in lung cancer patients with a high misdiagnosis rate and high mortality. This study was to investigate the clinical characteristics, diagnosis and treatment approaches for lung cancer accompanied by PE, thus to improve the diagnosis and treatment efficacy of this disease., Methods: Clinical manifestations, comorbid conditions, risk factors, laboratory (indirect) and imaging examinations (direct) and treatment methods of 23 lung cancer patients with PE were retrospectively analyzed., Results: Among the 23 patients, 14(60.87%) had hypoxemia, all (100%) had elevated serum D-dimer, 11 (47.83%) had characteristic changes in electrocardiogram. Ten out of 12 cases (83.33%) examined by computed tomography angiography were found filling defect in the pulmonary artery; all two case receiving isotope perfusion scanning were detected segmental perfusion defect in the lung; one case undergoing MRI was found segmental filling defect in the pulmonary artery; and one case was discovered the direct sign of PE by pulmonary arteriography. The medium survival time (MST) of five cases who received symptomatic treatment was 13 days, of four cases who received thrombolysis therapy was 22.5 days, of 12 cases who underwent anticoagulation and chemotherapy was 93 days, and of two cases who were only given anticoagulant therapy were 70 days and 189 days respectively., Conclusions: Diagnosis of lung cancer accompanied by PE mainly depends on direct examinations. Thrombolysis and anticoagulation therapy are recommended for those patients. In addition, chemotherapy may also be considered.
- Published
- 2009
13. [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
- Author
-
Wang ZH, Guo J, Chen Z, Li CZ, Sheng LJ, Zhou DG, Liu B, Liu J, Wang QC, and Zhang EN
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma, Mucinous drug therapy, Adenocarcinoma, Mucinous pathology, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Docetaxel, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Follow-Up Studies, Humans, Leucovorin administration & dosage, Leucovorin adverse effects, Leukopenia chemically induced, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Lung Neoplasms drug therapy, Lung Neoplasms secondary, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds adverse effects, Oxaliplatin, Remission Induction, Stomach Neoplasms pathology, Taxoids administration & dosage, Taxoids adverse effects, Vomiting chemically induced, Young Adult, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms drug therapy
- Abstract
Objective: To evaluate the efficacy and toxicity of a biweekly DOF regimen consisting of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer., Methods: The biweekly DOF regimen was administered in 37 advanced gastric cancer patients. Docetaxel, oxaliplatin and leucovorin were given intravenously at a dose of 35 mg/m2, 85 mg/m2 and 200 mg/m2 for 1 h, 2 h and 2 h on D1, respectively, and 5-Fu was administered as continuous intravenous infusion for 48 h at a dose of 1500 mg/m2 on D1 and D2. This regimen was repeated every 2 weeks. The efficacy and toxicity were evaluated after completion of 3 cycles at least., Results: The overall response rate (RR) of this series was 67.6%, complete response rate and partial response rate were 27.0% and 40.5%, respectively. The time to progression (TTP) was 9.2 months, and median survival time (MST) was 13.7 months. The RRs of 11 chemotherpy-naïve patients and 26 patients pre-treated with chemotherapy were 81.8% and 61.5%, respectively., Conclusion: Our preliminary results showed that this biweekly combination regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin is effective and tolerable for advanced gastric cancer. However, further investigation of this regimen is mandatory.
- Published
- 2008
14. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
- Author
-
Dong M, Feng FY, Zhang Y, Xie GR, Wang YJ, Liu JW, Song ST, Zhou QH, Ren J, Jiao SC, Li J, Wang XW, Chen Q, Wang ZH, Xu N, and Feng JF
- Subjects
- Adult, Aged, Analgesics adverse effects, Analgesics therapeutic use, Bone Density Conservation Agents adverse effects, Bone Density Conservation Agents therapeutic use, Bone Neoplasms complications, Breast Neoplasms pathology, Collagen Type I urine, Colorectal Neoplasms pathology, Creatinine urine, Diphosphonates adverse effects, Double-Blind Method, Female, Fever chemically induced, Humans, Imidazoles adverse effects, Lung Neoplasms pathology, Male, Middle Aged, Pain Measurement, Pain, Intractable etiology, Pain, Intractable urine, Pamidronate, Peptides urine, Prospective Studies, Vomiting chemically induced, Zoledronic Acid, Bone Neoplasms secondary, Diphosphonates therapeutic use, Imidazoles therapeutic use, Multiple Myeloma complications, Pain, Intractable drug therapy
- Abstract
Objective: To evaluate the efficacy and safety of zoledronic acid in the treatment of bone pain in patients with bone metastasis from solid tumor or multiple myeloma., Methods: A randomized, double-blind, double-simulated and multi-center phase III clinical trail with pamidronate as control was conducted. Patients with moderate to severe bone pain (VAS > 50 mm) induced by solid tumor or multiple myeloma were randomized to receive intravenous zoledronic acid 4 mg or pamidronate 90 mg. Then the change of VAS and urinary NTX/Cr and CTX/Cr were observed in two groups., Results: From July 2005 to September 2006, 228 patients with bone pain induced by bone metastasis from 15 cancer centers were randomize into two groups: 116 patients in zoledronic acid group and 112 patients in pamidronate group. The VAS value was decreased gradually after treatment in these two groups. Significant improvement in bone pain after treatment were observed both in zoledronic acid group and the control group when compared with baseline VAS on D8 (-11.77% vs. -10.87%), D15 (-24.60% vs. -21.06%) and D28 (-32.37% vs. -31.26%) (P< or =0.0001), but no significant difference existed between two groups (P =0.6587). Compared with baseline, urine NTX/Cr and CTX/Cr level were decreased rapidly after treatment in both groups, the nadir was on D8, the median decreased on D28, which was -36.9% vs. -32.1% for NTX/Cr (P = 0.7922) and -63.2% vs. -47.9% for CTX/Cr (P =0.834). The frequently observed adverse events were pyrexia (19.0% vs. 31.3%), vomiting (6.0% vs. 8.9%), nausea (4.3% vs. 4.5%), fatigue (3.4% vs. 2.7%) and constipation (2.6% vs. 1.8%) in the two groups. Compared with baseline, the serum creatinine level was not significantly increased throughout the study., Conclusion: Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety.
- Published
- 2008
15. [Association of gene polymorphisms in the DNA repair gene XPD with risk of non-Hodgkin's lymphoma].
- Author
-
Song B, Zhu JY, Liu J, Wang ZH, Shi Y, Lü LY, and Zheng Y
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Point Mutation, Risk Factors, Young Adult, DNA Repair, Lymphoma, Non-Hodgkin genetics, Polymorphism, Genetic, Xeroderma Pigmentosum Group D Protein genetics
- Abstract
This study was aimed to explore the relationship between the single nucleotide polymorphisms of XPD (G23591A, A35931C) and individual susceptibility to non-Hodgkin's lymphomas (NHL) in Shandong populations. XPD gene polymorphism in 309 cases of NHL and 305 healthy controls were detected using PCR-restriction fragment length polymorphism assay in a case-control molecular epidemiology study. The association between gene polymorphism and the risk of NHL were examined through comparing odds ratio (OR) and 95% confidence interval (CI) between two groups. The results showed that no significant association between the XPD (G23591A, A35931C) polymorphism and the risk of whole NHL was shown at first. In the further analysis, all NHL cases were divided into four groups: follicular lymphoma (FL) group, diffuse large B-cell lymphoma (DLBCL) group, T-cell lymphoma group and other B-cell lymphoma group. Frequencies of XPD 23591GA + AA genotypes were 16.3%, 18.0%, 10.5% and 18.4% in each subgroup respectively, while 12.5% in control. Individuals carrying GA + AA genotype had 1.43, 1.58, 0.89 and 1.50-fold risk of NHL sub groups as much as GG genotype, but no statistically significant difference between subgroups and control was found (p>0.05); frequencies of XPD 35931AC + CC genotypes were 15.2%, 15.8%, 18.4% and 12.5% in each subgroup, while 11.5% in control. Individuals carrying AC + CC genotype had 1.41, 1.48, 1.75 and 1.12-fold risk of NHL subgroup as much as AA genotype, but there were also no statistically significant difference between each subgroup and control (p>0.05). It is concluded that the gene polymorphism of XPD (G23591A, G935931C) does not associate with the risk of developing NHL in Shandong populations.
- Published
- 2008
16. [Clinical significance of cytokeratin 19 mRNA expression in peripheral leucocytes in patients with non-small cell lung cancer].
- Author
-
Wang ZH, Kong L, and Liu J
- Subjects
- Adult, Aged, Biomarkers, Tumor analysis, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung genetics, Cell Differentiation, Female, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms blood, Lung Neoplasms genetics, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Survival Analysis, Carcinoma, Non-Small-Cell Lung pathology, Keratin-19 genetics, Leukocytes metabolism, Lung Neoplasms pathology, RNA, Messenger biosynthesis
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.